Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to $2.8 million.

  • Zevra Therapeutics' Share-based Compensation fell 5484.76% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.4 million, marking a year-over-year increase of 6.47%. This contributed to the annual value of $14.9 million for FY2024, which is 15035.27% up from last year.
  • As of Q3 2025, Zevra Therapeutics' Share-based Compensation stood at $2.8 million, which was down 5484.76% from $2.5 million recorded in Q2 2025.
  • Over the past 5 years, Zevra Therapeutics' Share-based Compensation peaked at $6.1 million during Q3 2024, and registered a low of $318000.0 during Q2 2021.
  • Moreover, its 5-year median value for Share-based Compensation was $1.4 million (2023), whereas its average is $1.8 million.
  • As far as peak fluctuations go, Zevra Therapeutics' Share-based Compensation soared by 37484.28% in 2022, and later tumbled by 5484.76% in 2025.
  • Quarter analysis of 5 years shows Zevra Therapeutics' Share-based Compensation stood at $823000.0 in 2021, then rose by 16.04% to $955000.0 in 2022, then surged by 54.14% to $1.5 million in 2023, then soared by 172.96% to $4.0 million in 2024, then crashed by 31.04% to $2.8 million in 2025.
  • Its Share-based Compensation was $2.8 million in Q3 2025, compared to $2.5 million in Q2 2025 and $3.1 million in Q1 2025.